Antech Expands Molecular Diagnostic Offers

Cancer diagnoses, from digital cytology and advanced imaging to new molecular tests, are helping veterinarians combat the leading cause of canine death

Antech’s cancer diagnostics portfolio now includes SearchLight DNA from Vidium Animal Health and OncoK9 from PetDx. These new tests add to Antech’s range of canine cancer diagnostics that includes multiple primary diagnostic methods, including ultrasound, digital cytology, and molecular medicine.

SearchLight DNA is a genetic test that analyzes the DNA of dog cancer cells, looking for mutations across 120 related cancer genes, to identify mutations that aid in cancer diagnosis and prediction and help guide treatment decisions.

OncoK9 is a “liquid biopsy” multiple cancer early detection (MCED) “liquid biopsy” test that helps veterinarians detect 30 different types of cancer, including 8 of the most common cancers in dogs. OncoK9 has been clinically validated by the CANDiD (Canine Cancer Detection) study using samples collected prospectively from more than 1,000 customer-owned dogs across more than 40 clinical sites, according to a release from Antech.1

“A cancer diagnosis can be devastating for a pet owner,” said Sue Ettinger, DVM, DACVIM (Oncology). Accurate diagnosis and care can be expensive and complex. When reading tumor genomic material, molecular diagnostics gives us an unprecedented level of transparency into the nature of cancer, allowing us to diagnose it early and formulate a highly personalized treatment plan.”

According to an Antech press release, the ability of these advanced diagnostic tests to analyze the DNA of cancer cells provides specific information about mutations that cause cancer growth and spread and can help veterinarians identify cancer often when it is most treatable. Molecular diagnosis may also help veterinarians understand the origin and behavior of cancer, which may guide the optimal approach to treatment.1

“Cancer has been and continues to be a frustrating disease for pet owners and veterinarians to diagnose and treat,” said Kathleen Mix, MS, DVM, DACVIM, Vice President of Medical Operations at Antech. “Antech is dedicated to the continuous advancement of our diagnostic capabilities in oncology to help provide innovative ways in which we diagnose this disease compared to traditional methods. This will allow us to improve the quality of care by diagnosing these diseases sooner than in the past and avoiding delays in starting treatment” .

“Cancer has taken the lives of far too many beloved dogs, too soon and for too long,” said Loni Schoff, president of Antech. “I believe we are on the brink of a new era in canine cancer care; one that offers new hope for veterinarians and pet owners alike. That’s why we’re expanding our range of canine cancer diagnoses. From molecular diagnostics to pathology expertise to being the most trusted provider in medicine. Veterinary Digital X-Ray, Ultrasound, Laser Therapy, CT Scan, Imaging Support and PACS We will continue to provide veterinarians with the most advanced diagnostic tools to effectively combat this terrible disease.Introducing the latest molecular diagnostics for cancer detection and personalized treatment is simply the right thing to do. We will continue to do everything in our power as we strive to help veterinary teams attack this leading cause of canine death.”


Antech expands its molecular diagnostics offering into the most comprehensive range of veterinary diagnostics for canine cancer. Antech Diagnosis. September 12, 2022. Accessed September 15, 2022.